association

Full identifier: http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association

Assigned to 1 class:

Minted in Nanopublication

 RA8N_evLf_ comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA8N_evLf_...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders e g spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders if improvement occurs it will ordinarily occur within the dosage titration see dosage and administration occasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsules therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression a decision to continue the administration of dantrolene sodium capsules on a long term basis is justified if introduction of the drug into the patient s regimen produces a significant reduction in painful and or disabling spasticity such as clonus or permits a significant reduction in the intensity and or degree of nursing care required or rids the patient of any annoying manifestation of spasticity considered important by the patient himself oral dantrolene sodium capsules is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia and or surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodium oral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8N_evLf_... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T15:32:33.425+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8N_evLf_... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8N_evLf_... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8N_evLf_... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA8N_evLf_...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA8N_evLf_... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA8N_evLf_...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 12 Jun 2021, 13:32:33 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders e g spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders if improvement occurs it will ordinarily occur within the dosage titration see dosage and administration occasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsules therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression a decision to continue the administration of dantrolene sodium capsules on a long term basis is justified if introduction of the drug into the patient s regimen produces a significant reduction in painful and or disabling spasticity such as clonus or permits a significant reduction in the intensity and or degree of nursing care required or rids the patient of any annoying manifestation of spasticity considered important by the patient himself oral dantrolene sodium capsules is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia and or surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodium oral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T13:32:33.425Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)